Literature DB >> 18525437

Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C.

Vincent Ho1, Anna Mclean, Shaughan Terry.   

Abstract

We report the case of a 43-year-old man who developed systemic lupus erythematosus (SLE) after receiving pegylated alpha-interferon and ribavirin for chronic hepatitis C. He displayed 8 features of the American College of Rheumatology criteria for SLE: glomerulonephritis, arthritis, serositis, a florid discoid rash, lymphopenia, oral ulcers, the development of high titers of antinuclear antibodies, and antidouble stranded DNA antibodies. Furthermore, his admission was complicated by the development of life threatening myopericarditis and vasculitis. This case is notable for the clinical severity and nature of multiorgan lupus involvement from hepatitis C antiviral therapy. Clinical signs of SLE have resolved and anti DS DNA has normalized.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18525437     DOI: 10.1097/RHU.0b013e3181775e80

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  20 in total

1.  Interferon alpha-induced lupus: proof of principle.

Authors:  Timothy B Niewold
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

2.  Lupus activation with cerebritis following pegylated interferon in a hemodialysis patient.

Authors:  Sanjay Kumar Agarwal; Charanjeet Lal; Sabahat Husain Zaidi
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

Review 3.  Dendritic cells in systemic lupus erythematosus.

Authors:  Heather M Seitz; Glenn K Matsushima
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

4.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.

Authors:  Xuan Feng; Nicholas P Reder; Mounica Yanamandala; Addie Hill; Beverly S Franek; Timothy B Niewold; Anthony T Reder; Adil Javed
Journal:  J Neurol Sci       Date:  2011-10-27       Impact factor: 3.181

Review 5.  Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.

Authors:  Yi-chi M Kong; Wei-Zen Wei; Yaron Tomer
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

6.  Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons.

Authors:  Rivka C Stone; Di Feng; Jing Deng; Sukhwinder Singh; Lisong Yang; Patricia Fitzgerald-Bocarsly; Maija-Leena Eloranta; Lars Rönnblom; Betsy J Barnes
Journal:  Arthritis Rheum       Date:  2012-03

7.  Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Authors:  Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

Review 8.  Interferon alpha in systemic lupus erythematosus.

Authors:  Timothy B Niewold; Daniel N Clark; Rafah Salloum; Brian D Poole
Journal:  J Biomed Biotechnol       Date:  2010-06-29

Review 9.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

10.  Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.

Authors:  Yao Yuan; Siddha Kasar; Chingiz Underbayev; Daniel Vollenweider; Erica Salerno; Sergei V Kotenko; Elizabeth Raveche
Journal:  Mol Immunol       Date:  2012-05-11       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.